BRPI0419110A - antagonistas de bifenil integrina - Google Patents

antagonistas de bifenil integrina

Info

Publication number
BRPI0419110A
BRPI0419110A BRPI0419110-2A BRPI0419110A BRPI0419110A BR PI0419110 A BRPI0419110 A BR PI0419110A BR PI0419110 A BRPI0419110 A BR PI0419110A BR PI0419110 A BRPI0419110 A BR PI0419110A
Authority
BR
Brazil
Prior art keywords
biphenyl
integrin antagonists
antagonists
integrin
integrine
Prior art date
Application number
BRPI0419110-2A
Other languages
English (en)
Inventor
Raj Nagarajan Srinivasan
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BRPI0419110A publication Critical patent/BRPI0419110A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ANTAGONISTAS DE BIFENIL INTEGRINA A invenção a seguir está direcionada a compostos e a composições farmacêuticas da Fórmula (I) úteis para o tratamento de estados de saúde mediados pela integrina <244>~ v~<225>~ 3~ e/ou <244>~ v~<225>~ 5~.
BRPI0419110-2A 2004-10-14 2004-10-14 antagonistas de bifenil integrina BRPI0419110A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/033981 WO2006043930A1 (en) 2004-10-14 2004-10-14 Biphenyl integrin antagonists

Publications (1)

Publication Number Publication Date
BRPI0419110A true BRPI0419110A (pt) 2007-12-11

Family

ID=34959012

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0419110-2A BRPI0419110A (pt) 2004-10-14 2004-10-14 antagonistas de bifenil integrina

Country Status (7)

Country Link
US (1) US20080064716A1 (pt)
EP (1) EP1802618A1 (pt)
JP (1) JP2008516947A (pt)
BR (1) BRPI0419110A (pt)
CA (1) CA2584041A1 (pt)
MX (1) MX2007004535A (pt)
WO (1) WO2006043930A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9345739B2 (en) * 2007-11-08 2016-05-24 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
SI3929196T1 (sl) 2013-09-24 2023-11-30 Fujifilm Corporation Farmacevtska sestava spojine, ki vsebuje dušik ali njegovo sol ali njegov kovinski kompleks

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2250464A1 (en) * 1996-03-29 1997-10-09 G.D. Searle & Co. Meta-substituted phenylene derivatives and their use as alphavbeta3 integrin antagonists or inhibitors
DE19939981A1 (de) * 1999-08-24 2001-03-01 Merck Patent Gmbh Neue Inhibitoren des Integrins alphavß3
US20020072518A1 (en) * 2000-08-29 2002-06-13 Khanna Ish Kumar Bicyclic alphavbeta3 antagonists
WO2002018340A1 (en) * 2000-08-30 2002-03-07 Pharmacia Corporation GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS

Also Published As

Publication number Publication date
US20080064716A1 (en) 2008-03-13
JP2008516947A (ja) 2008-05-22
EP1802618A1 (en) 2007-07-04
WO2006043930A1 (en) 2006-04-27
CA2584041A1 (en) 2006-04-27
MX2007004535A (es) 2007-06-08

Similar Documents

Publication Publication Date Title
BRPI0619153A8 (pt) derivados de 4-aminopirroltriazina substituída, e composição farmacêutica
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
DE602004013563D1 (de) Rantagonisten
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
ATE423122T1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
BRPI0410630A (pt) antagonista de nk1
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200970156A1 (ru) Пиридизиноновые производные
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
BRPI0512273A (pt) inibidores do fator xa
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
ATE537170T1 (de) Cgrp-rezeptorantagonisten
WO2006047415A3 (en) FACTOR Xa COMPOUNDS
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
TW200745122A (en) New compounds I
PL376324A1 (en) Piperazinyl and diazapanyl benzamides and benzthioamides
UY30787A1 (es) &#34;inhibidores benzoimidazolicos de trpv1&#34;
SE0403171D0 (sv) New compounds
DE60219911D1 (de) Pyrrolidin-2-on derivate als faktor xa inhibitoren
DE602005009512D1 (de) 3-((hetero)arylsulfonyl)-8-ä(aminoalkyl)oxyüchinoline als antagonisten des 5-ht6-rezeptors zur behandlung von erkrankungen des zns
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
MY158069A (en) Tricyclic compound and pharmaceutical use thereof

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.